• Product NameAZD-9291 mesylate?
• Brief DescriptionInhibitors
• Purification99.46%
• Biological ActivityAZD-9291 is a third-generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients with advanced lung Ys that have become resistant to existing EGFR inhibitors. AZD9291 is highly active in preclinical models and is well tolerated in animal models. It inhibits both activating and resistant EGFR mutations while sparing the normal form of EGFR that is present in normal skin and gut cells, thereby reducing the side effects encountered with currently available medicines.
• Target NameEGFR inhibitor
• CAS No. 1421373-66-1
• Calculated MW 595.71
• Formulation C29H37N7O5S
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Cancer
  SMILES:CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O
  Pathways:Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors
  Receptor:EGFR (L858R); EGFR (L858R/T790M)
  Boling pt:
  Melting pt:
  Solubility:Soluble in DMSO
  Appearance:Powder
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Patent WO 2013014448 A1: 2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating Y .

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting